Osteopontin expression correlates with poorer survival in GBM (Atai et al, 2011; Wei et al, 2019), and its expression is enriched in mesenchymal as compared to classical and pro‐neural tumours (Wei et al, 2019). This evidence concerns the gene SPP1 and glioblastoma.